Skip to main content

Table 3 Structures and in vitro anti-cancer activity of identified GpM components

From: Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)

Compd R1

R2

R3

R4

R5

R6

Anti-cancer activitya

Reference

1

H

H

CH3

H

47.12 (HL-60)

[122]

2

H

H

CH3

H

45.50 (HL-60)

[122]

3

H

H

CH3

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

4

H

H

CH3

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

5

H

H

CHO

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

6

H

H

CHO

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

7

CH3

H

CHO

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

8

CH3

H

CHO

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

9

CH3

H

CH3

H

HL-60, Colon 205, Du145, GC-7901, BEL-7402

[85, 86]

10

CH3

H

CH3

OH

67.66 ± 3.36 (HL-60), 18.45 ± 0.93 (MCF-7), 34.95 ± 0.93(HT-29), 20.97 ± 1.49 (A549), 27.68 ± 1.58 (SK-OV-3)

[53]

11

CH3

H

CH3

=O

>109.2 (HL-60), 42.81 ± 3.60 (MCF-7), 22.06 ± 2.18 (HT-29), 31.45 ± 2.62 (A549), 30.25 ± 1.53 (SK-OV-3)

[53]

12

CH3

H

CH3

=O

>107.6 (HL-60), 23.03 ± 1.40 (MCF-7), 46.30 ± 1.08 (HT-29), 21.09 ± 1.18 (A549), 35.62 ± 0.97 (SK-OV-3)

[53]

13

CH3

H

CH3

=O

76.63 ± 2.98 (HL-60), 23.62 ± 1.02 (MCF-7), 39.34 ± 1.02 (HT-29), 19.90 ± 1.40 (A549), 19.90 ± 1.49 (SK-OV-3)

[53]

14

H

H

CH3

H

7.44 (HL-60), 27.80 (Colon 205), 24.12 (Du145)

[127]

15

H

H

H

CH3

H

3.90 (MDA-MB-435)

[128]

16

H

H

H

CH3

H

0.05 ± 0.01 (A549), 0.25 ± 0.07 (U87)

[129]

17

H

OH

H

CH3

OH

12.54 ± 0.53 (A549)

[130]

18

H

OH

CH3

OH

34.94 ± 4.23 (A549)

[130]

19

H

H

H

CH3

H

40 ± 0.7 (HepG2)

[44]

20

H

H

H

CH3

OH

38 ± 0.5 (HepG2)

[44]

21

H

H

H

CH3

H

41.89 (HCT116), 20.94 (HT-29), 32.61 (MCF-7)

[55]

22

H

H

H

CH3

H

41.40 (HCT116), 19.00 (HT-29), 28.82 (MCF-7)

[55]

23

H

H

CHO

H

32.00 ± 1.24 (HepG2)

[56]

24

H

H

CH3

H

21.38 ± 1.06 (HepG2)

[56]

25

H

OH

CH3

OH

74.3 ± 1.9 (A549)

[59]

26

18.41 (HT-29), 4.46 (MCF-7), 9.39 ± 0.9 (DI145), 6.93 ± 0.5 (22RV-1)

[54, 55]

27

20.38 (HT-29), 13.51 (MCF-7)

[55]

28

16.14 (HT-29), 8.84 (MCF-7)

[55]

Flavonoid fraction

33.3 (PC-3)

[21]

Carotenoid fraction

1.6 (Hep3B)

[84]

Chlorophyll fraction

57.5 (Hep3B)

[84]

Nonpolar fraction

38.02 ± 2.98 (MDA-MB-453), 31.62 ± 1.76 (HCT116), 35.48 ± 3.81 (LNCaP), 35.48 ± 6.45 (MCF7)

[22]

Gypenosides

47.6 (Hep3B), 39.3 (PC-3), 30.6 (A549) HL-60, MCF-7, HT-29, Colon 205, Du145, MDA-MB-435, U87, A549, SK-OV-3, HepG2, SGC-7901, BEL-7402, Huh-7, HA22T, SW620, Eca-109, SAS, L1210, WEHI-3, SW-480, KB/VCR, MCF-7/ADR

[19, 21, 36, 44, 85–87, 89–91, 105–109, 111, 112, 114, 115, 119, 121, 131, 132]

Polysaccharide

65.4 (B16), HT-29, B16, Hela, SW-1116, HepG2

[44, 87, 88, 119]

Ethanolic extract

C6, HT-59

[113, 133]

  1. aThe anti-cancer activities, IC50 (μg/ml), of components of GpM are expressed as mean ± SD following cell line names in bracket. Only the mean value is listed if there is no SD value available and only cancer cell line name is listed if no IC50 data is available. The unit of compound 10, 11, 12, 13, 16, 21, 22, 26, 27 and 28 are transformed based on molecular weight. This table also presents 30 cancer cell lines whose proliferation could be inhibited by GpM, which indicates that GpM exerts broad spectrum anti-cancer activities